Overview

PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients

Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of PF-06291874 in Type 2 Diabetes patients.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer